Author

Kate Lynette Mahon

Observed names: K L Mahon, K. L. Mahon, K. Mahon, K.L. Mahon, KL Mahon, Kate L Mahon, Kate L. Mahon, Kate Mahon

Observed institutions: The University of Sydney, Garvan Institute of Medical Research, Royal Prince Alfred Hospital, Concord Repatriation General Hospital, UNSW Sydney, St Vincent's Hospital Sydney, Chris O’Brien Lifehouse, St Vincent's Clinic, The Christie NHS Foundation Trust, The Kinghorn Cancer Centre, Monash University

ORCID: 0000-0002-6801-0841

Observed ORCID: 0000-0002-6801-0841

OpenAlex ID: A5002877928

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

2018 · Louise Emmett, Megan Crumbaker, et al. · Clinical Genitourinary Cancer · 185

Methylated circulating tumor DNA in blood: power in cancer prognosis and response

2016 · Kristina Warton, Kate L Mahon, et al. · Endocrine Related Cancer · 177

PDF

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

2020 · Manish Kohli, Winston Tan, et al. · EBioMedicine · 137

PDF

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

2014 · H-M Lin, L Castillo, et al. · British Journal of Cancer · 135

PDF

Management of colorectal cancer

2019 · Kilian G M Brown, Michael J Solomon, et al. · BMJ · 103

Pathways of chemotherapy resistance in castration-resistant prostate cancer

2011 · Kate L Mahon, Susan M Henshall, et al. · Endocrine Related Cancer · 90

PDF

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

2014 · K L Mahon, W Qu, et al. · British Journal of Cancer · 89

PDF

A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer

2017 · Hui‐Ming Lin, Kate L. Mahon, et al. · International Journal of Cancer · 84

PDF

Mainstream consent programs for genetic counseling in cancer patients: A systematic review

2020 · Tahlia Scheinberg, Alison Young, et al. · Asia-Pacific Journal of Clinical Oncology · 69

PDF

Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer

2020 · Heidi Fettke, Edmond M. Kwan, et al. · European Urology · 63

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

2017 · Hui-Ming Lin, Kate L Mahon, et al. · British Journal of Cancer · 56

PDF

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

2021 · Hui-Ming Lin, Blossom Mak, et al. · EBioMedicine · 55

PDF

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

2015 · K L Mahon, H-M Lin, et al. · British Journal of Cancer · 53

PDF

Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer

2020 · Tahlia Scheinberg, Annabel Goodwin, et al. · JCO Oncology Practice · 52

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

2023 · Heidi Fettke, Chao Dai, et al. · EBioMedicine · 49

PDF

Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long‐term follow‐up

2017 · Judith Grogan, Ruta Gupta, et al. · British Journal of Urology · 45

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer

2018 · Sarah Q. To, Edmond M. Kwan, et al. · European Urology · 44

Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

2021 · Edmond M. Kwan, Chao Dai, et al. · JCO Precision Oncology · 42

PDF

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial

2018 · Kate L. Mahon, Wenjia Qu, et al. · European Urology · 41

The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions

2022 · Madeleine C. Strach, Sarah Sutherland, et al. · Therapeutic Advances in Medical Oncology · 37

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer

2021 · Hui-Ming Lin, Kevin Huynh, et al. · Prostate Cancer and Prostatic Diseases · 31

Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer

2020 · Dushan Miladinovic, Thomas Cusick, et al. · Cancers · 26

PDF

Somatic mutations in salivary duct carcinoma and potential therapeutic targets

2017 · Timothy K. Khoo, Bing Yu, et al. · Oncotarget · 24

PDF

A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer

2017 · A.Y. Zhang, J.S. Grogan, et al. · Annals of Oncology · 24

Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis

2021 · Udit Nindra, Adel Shahnam, et al. · Asia-Pacific Journal of Clinical Oncology · 22

PDF

Works count: 103

Citation count: 2,002

H-index: 24

I10-index: 37